New EGA group to promote access to ''value-added'' drugs
This article was originally published in Scrip
The EGA, which represents generics and biosimilars companies in Europe, has set up a new internal group to help increase patient access to value-added off-patent medicines such as those that improve compliance or offer a different delivery route from the originator medicine.
You may also be interested in...
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.